Adriaan Alexander Voors

Adriaan Alexander Voors

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Adriaan Alexander Voors

Department of Cardiology, University Medical Center Groningen University of Groningen Groningen The Netherlands

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2016 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
PPPiotr Ponikowski
Piotr Ponikowski
AVAdriaan A. Voors
Adriaan A. Voors
SAStefan D. Anker
Stefan D. Anker
HBHéctor Bueno
Héctor Bueno
JCJohn G. F. Cleland
John G. F. Cleland
DRDocument Reviewers
Document Reviewers

28 February 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
AVAdriaan A. Voors
Adriaan A. Voors
CAChristiane E. Angermann
Christiane E. Angermann
JTJohn R. Teerlink
John R. Teerlink
SCSean P. Collins
Sean P. Collins
MKMikhail Kosiborod
Mikhail Kosiborod
PPPiotr Ponikowski
Piotr Ponikowski
The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in patients who are hospitalized for acute heart failure is unknown. In this double-blind trial (EMPULSE; NCT04157751), 530 patients with a primary diagnosis of acute de novo or decompensated chronic heart failure regardless of left ventricular ejection fraction were randomly assigned to receive empagliflozin 10 mg once daily or placebo. Patients were randomized in-hospital when clinically stable (median time from hospital admission to randomization, 3 days) and were treated for up to 90 days. The primary outcome of the trial was clinical benefit, defined as a hierarchical composite of death from any cause, number of heart failure events and time to first heart failure event, or a 5 point or greater difference in change from baseline in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score at 90 days, as assessed using a win ratio. More patients treated with empagliflozin had clinical benefit compared with placebo (stratified win ratio, 1.36; 95% confidence interval, 1.09–1.68; P = 0.0054), meeting the primary endpoint. Clinical benefit was observed for both acute de novo and decompensated chronic heart failure and was observed regardless of ejection fraction or the presence or absence of diabetes. Empagliflozin was well tolerated; serious adverse events were reported in 32.3% and 43.6% of the empagliflozin- and placebo-treated patients, respectively. These findings indicate that initiation of empagliflozin in patients hospitalized for acute heart failure is well tolerated and results in significant clinical benefit in the 90 days after starting treatment.

7 January 2020 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
KDKevin Damman
Kevin Damman
JBJoost C. Beusekamp
Joost C. Beusekamp
EBEva M. Boorsma
Eva M. Boorsma
HSHenk P. Swart
Henk P. Swart
TSTom D.J. Smilde
Tom D.J. Smilde
AVAdriaan A. Voors
Adriaan A. Voors
Aims Inhibition of sodium–glucose co‐transporter 2 (SGLT2) reduces the risk of death and heart failure (HF) admissions in patients with chronic HF. However, safety and clinical efficacy of SGLT2 inhibitors in patients with acute decompensated HF are unknown. Methods and results In this randomized, placebo‐controlled, double‐blind, parallel group, multicentre pilot study, we randomized 80 acute HF patients with and without diabetes to either empagliflozin 10 mg/day or placebo for 30 days. The primary outcomes were change in visual analogue scale (VAS) dyspnoea score, diuretic response (weight change per 40 mg furosemide), change in N‐terminal pro brain natriuretic peptide (NT‐proBNP), and length of stay. Secondary outcomes included safety and clinical endpoints. Mean age was 76 years, 33% were female, 47% had de novo HF and median NT‐proBNP was 5236 pg/mL. No difference was observed in VAS dyspnoea score, diuretic response, length of stay, or change in NT‐proBNP between empagliflozin and placebo. Empagliflozin reduced a combined endpoint of in‐hospital worsening HF, rehospitalization for HF or death at 60 days compared with placebo [4 (10%) vs. 13 (33%); P = 0.014]. Urinary output up until day 4 was significantly greater with empagliflozin vs. placebo [difference 3449 (95% confidence interval 578–6321) mL; P < 0.01]. Empagliflozin was safe, well tolerated, and had no adverse effects on blood pressure or renal function. Conclusions In patients with acute HF, treatment with empagliflozin had no effect on change in VAS dyspnoea, diuretic response, NT‐proBNP, and length of hospital stay, but was safe, increased urinary output and reduced a combined endpoint of worsening HF, rehospitalization for HF or death at 60 days.

19 December 2013 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
VDVincent M. van Deursen
Vincent M. van Deursen
RURenato Urso
Renato Urso
CLCecile Laroche
Cecile Laroche
KDKevin Damman
Kevin Damman
UDUlf Dahlström
Ulf Dahlström
AVAdriaan A. Voors
Adriaan A. Voors

14 May 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ISIziah E Sama
Iziah E Sama
ARAlice Ravera
Alice Ravera
BSBernadet T Santema
Bernadet T Santema
Harry Van GoorHarry Van Goor
Harry Van Goor
JMJozine M ter Maaten
Jozine M ter Maaten
AVAdriaan A Voors
Adriaan A Voors
The current pandemic coronavirus SARS-CoV-2 infects a wide age group but predominantly elderly individuals, especially men and those with cardiovascular disease. Recent reports suggest an association with use of renin–angiotensin–aldosterone system (RAAS) inhibitors. Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for coronaviruses. Higher ACE2 concentrations might lead to increased vulnerability to SARS-CoV-2 in patients on RAAS inhibitors. We measured ACE2 concentrations in 1485 men and 537 women with heart failure (index cohort). Results were validated in 1123 men and 575 women (validation cohort). The median age was 69 years for men and 75 years for women. The strongest predictor of elevated concentrations of ACE2 in both cohorts was male sex (estimate = 0.26, P < 0.001; and 0.19, P < 0.001, respectively). In the index cohort, use of ACE inhibitors, angiotensin receptor blockers (ARBs), or mineralocorticoid receptor antagonists (MRAs) was not an independent predictor of plasma ACE2. In the validation cohort, ACE inhibitor (estimate = –0.17, P = 0.002) and ARB use (estimate = –0.15, P = 0.03) were independent predictors of lower plasma ACE2, while use of an MRA (estimate = 0.11, P = 0.04) was an independent predictor of higher plasma ACE2 concentrations. In two independent cohorts of patients with heart failure, plasma concentrations of ACE2 were higher in men than in women, but use of neither an ACE inhibitor nor an ARB was associated with higher plasma ACE2 concentrations. These data might explain the higher incidence and fatality rate of COVID-19 in men, but do not support previous reports suggesting that ACE inhibitors or ARBs increase the vulnerability for COVID-19 through increased plasma ACE2 concentrations.

1 February 2022 in JACC: Heart Failure
Verified
Journal Article
Closed access
JTJasper Tromp
Jasper Tromp
WOWouter Ouwerkerk
Wouter Ouwerkerk
DVDirk J. van Veldhuisen
Dirk J. van Veldhuisen
HHHans L. Hillege
Hans L. Hillege
ARA. Mark Richards
A. Mark Richards
AVAdriaan A. Voors
Adriaan A. Voors